Видео ютуба по тегу Trial: Keynote-942

3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma
3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma
KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma
KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab ...
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab ...
Pembrolizumab + mRNA-4157, update a 3 anni del KEYNOTE-942
Pembrolizumab + mRNA-4157, update a 3 anni del KEYNOTE-942
Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival
Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
Ep 25: Best of ASCO 2024 with Jeff Weber
Ep 25: Best of ASCO 2024 with Jeff Weber
Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence
Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence
KEYNOTE-048 trial
KEYNOTE-048 trial
A personalized mRNA vaccine with pembrolizumab in melanoma
A personalized mRNA vaccine with pembrolizumab in melanoma
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
Ep 56: Best of 2024: ASCO
Ep 56: Best of 2024: ASCO
The First Cancer Vaccine is Here—This Changes Everything! | mRNA 4157 Explained
The First Cancer Vaccine is Here—This Changes Everything! | mRNA 4157 Explained
Individualized antigen therapy in melanoma
Individualized antigen therapy in melanoma
mRNA-4157, a novel mRNA vaccine, with pembrolizumab in melanoma
mRNA-4157, a novel mRNA vaccine, with pembrolizumab in melanoma
Сертификация ЦОД по стандарту TIA-942-A
Сертификация ЦОД по стандарту TIA-942-A
The future of personalized, neoantigen cancer vaccines
The future of personalized, neoantigen cancer vaccines